When did Recursion Pharmaceuticals, Inc. report Q4 2024 earnings?

Recursion Pharmaceuticals, Inc. (RXRX) reported Q4 2024 earnings on February 28, 2025 before market open.

What were Recursion Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?

Recursion Pharmaceuticals, Inc. reported revenue of $4.5M and eps of $-0.53 for Q4 2024.

Did Recursion Pharmaceuticals, Inc. beat estimates in Q4 2024?

Revenue missed the consensus estimate of $19.0M by $14.5M. EPS missed the consensus estimate of $-0.44 by $0.09.

Where can I find Recursion Pharmaceuticals, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001601830-25-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.

Recursion Pharmaceuticals, Inc. RXRX Q4 2024 Annual earnings

Reported February 28, 2025 · Before market open

Revenue$4.5MMiss by $14.5M

EPS-$0.53Miss by $0.09

Revenue estimate$19.0M

EPS estimate-$0.44

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$11.0M

EPS estimate-$0.25

Financials

Q4 2024

Income statement

See full

Revenue$4.5M-58.3%

Operating income-$183.8M-85.8%

Net income-$178.9M-92.4%

EPS (diluted)-$0.57-35.7%

Balance sheet

See full

Cash & equivalents$603.0M+50.2%

Total debt$135.1M+167%

Total equity$1.0B+123%

Total assets$1.4B+122%

Cash flow

See full

Operating cash flow-$115.4M-55.8%

CapEx$1.3M-37.2%

Free cash flow-$116.7M-53.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.64B+14.9%

Enterprise value$2.17B+11.6%

P/S44.9×-6.7×

Profitability

See full

Operating margin-814.1%+31.0pp

Net margin-788%+59.9pp

FCF margin-633.7%-34.5pp

Returns & leverage

See full

Return on equity-61.9%-5.9pp

Debt / equity0.1×0.0×

Current ratio3.8×-0.9×

Segments

By product

See full

Operating revenue$4.5M-57.5%

Grant revenue$35.0K-86.9%

By segment

See full

Reportable Segment$4.5M-59.2%

By geography

See full

Other$81.8K-57.5%

Versus estimates

Revenue

Q1 2026$6.3MMiss by $9.5M Q4 2025$35.4MBeat by $10.8M Q3 2025$5.2MMiss by $19.4M Q2 2025$19.1MMiss by $822.0K Q1 2025$14.7MBeat by $785.0K

Q4 2024$4.5MMiss by $14.5M

Diluted EPS

Q1 2026-$0.22Beat by $0.08 Q4 2025-$0.21Beat by $0.07 Q3 2025-$0.36Beat by $0.02 Q2 2025-$0.41Miss by $0.06 Q1 2025-$0.50Miss by $0.06

Q4 2024-$0.53Miss by $0.09

Ask the moment Recursion Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Recursion Pharmaceuticals, Inc. report Q4 2024 earnings?: Recursion Pharmaceuticals, Inc. (RXRX) reported Q4 2024 earnings on February 28, 2025 before market open.
What were Recursion Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?: Recursion Pharmaceuticals, Inc. reported revenue of $4.5M and eps of $-0.53 for Q4 2024.
Did Recursion Pharmaceuticals, Inc. beat estimates in Q4 2024?: Revenue missed the consensus estimate of $19.0M by $14.5M. EPS missed the consensus estimate of $-0.44 by $0.09.
Where can I find Recursion Pharmaceuticals, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001601830-25-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.